GENTIAN DIAGNOSTICS |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 45 NOK | -1.75% |
|
+5.14% | +8.43% |
| Apr. 30 | Gentian Diagnostics ASA Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| Apr. 30 | Transcript : Gentian Diagnostics ASA, Q1 2024 Earnings Call, Apr 30, 2024 |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- For several months, analysts have been revising their EPS estimates roughly upwards.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Over the past four months, analysts' average price target has been revised upwards significantly.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- Low profitability weakens the company.
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 92.08 times its estimated earnings per share for the ongoing year.
- With an enterprise value anticipated at 3.69 times the sales for the current fiscal year, the company turns out to be overvalued.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Sector: Medical Equipment, Supplies & Distribution
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| +8.43% | 66.82M | - | ||
| -6.76% | 12.28B | B+ | ||
| -5.68% | 8.05B | B- | ||
| +8.91% | 5.84B | B | ||
| +28.54% | 5.66B | C | ||
| -15.84% | 3.99B | C | ||
| +10.70% | 2.7B | - | - | |
| -61.12% | 2.7B | D+ | ||
| -6.99% | 2.39B | B- | ||
| +15.67% | 2.02B | C |
Investor Rating
Trading Rating
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
-
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- GENT Stock
- Ratings Gentian Diagnostics
